Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer's disease.

Huntington PotterJonathan H WoodcockTimothy D BoydChristina M CoughlanJohn R O'ShaughnessyManuel T BorgesAshesh A ThakerBalaibail A RajKatarzyna AdamszukDavid ScottVanesa AdamePaige AntonHeidi J ChialHelen GrayJoseph DanielsMichelle E StockerStefan H Sillau

Published in: Alzheimer's & dementia (New York, N. Y.) (2021)

The innate immune system is a viable target for therapeutic intervention in AD. An extended treatment trial testing the long-term safety and efficacy of GM-CSF/sargramostim in AD is warranted.

Keyphrases

immune response
randomized controlled trial
clinical trial
study protocol
combination therapy
replacement therapy